Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Дефект аортолегочной перегородки

Список литературы

  1. Андреева Н. С., Реброва О. Ю., Зорин Н. А., др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор 2012; 4: 10–24.
  2. Бураковский В.И., Бокерия Л.А. Руководство по сердечно-сосудистой хирургии. Москва. Медицина 1994.
  3. Джонс Кеннет Л.. Наследственные синдромы по Дэвиду Смиту. Атлас-справочник. Москва. Практика. 2011.
  4. Perloff Joseph K. Clinical recognition of Congenital Heart Disease. Fifth Edition. Saunders. 2003.
  5. Fotaki A., Novaes J., Jicinska H., Carvalho J.S. Fetal aortopulmonary window: case series and review of the literature. Ultrasound Obstet Gynecol. 2017 Apr;49(4):533-539. doi: 10.1002/uog.15936. 
  6. Burakowskii V.I. Anomalous derivation of the right coronary artery from the pulmonary artery with an interventricular septal defect.Grud Knir 1981;2:5-10.
  7. Burakowskii V.I. Diagnosis and surgical treatment of aorto-pulmonary defects associated with other congenital heart diseases. Grud Knir 1982;6: 13-21.
  8. Talwar S., Agarwal P., Choudhary S.K., Kothari S.S., Juneja R., Saxena A., Airan B. Aortopulmonary window: Morphology, diagnosis, and long-term results. J Card Surg. 2017 Feb;32(2):138-144. doi: 10.1111/jocs.12936.
  9. Бокерия Л.А., Горбачевский С.В., Шмальц А.А. Легочная артериальная гипертензия, ассоциированная с врожденными пороками сердца у взрослых (клиническая рекомендация). Грудная и сердечно-сосудистая хирургия. 2017; 59 (2): 135-147. DOI: 10.24022/0236-2791-2017-59-2-135-147
  10. Авдеев С.Н., Горбачевский С.В., Алдашев А.А. Легочная гипертензия. ГЭОТАР-Медиа. 2015.
  11. Tuder R.M., Abman S.H., Braun T., et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S3–S9.
  12. Oechslin E., Kiowski W., Schindler R., et al. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation 2005; 112:1106–1112.
  13. Белоконь Н.А., Подзолков В.П. Врожденные пороки сердца. Москва. Медицина. 1991.
  14. Castaneda A.R., Jonas R.A., Mayer J.E., Hanley F.L. Cardiac surgery of the neonate and infant. Philadelphia: WB Saunders Company, 1994:295–300.
  15. Банкл Г. Врожденные пороки сердца и крупных сосудов. Перевод с англ. Москва. Медицина. 1980.
  16. Berry T.E., Bharati S., Muster A.J., Idriss F.S., Santucci B., Lev M., Paul M.H. Distal aortopulmonary septal defect, aortic origin of the right pulmonary artery, intact ventricular septum, patent ductus arteriosus and hypoplasia of the aortic isthmus: a newly recognized syndrome. Am J Cardiol. 1982 Jan;49(1):108-16. doi: 10.1016/0002-9149(82)90284-3.
  17. Bharati S., Lev M. The Pathology of Congenital Heart Disease. A personal expierence of more than 6.300 Congenitally Malformed Hearts. Volume 1. P. 658.
  18. Jacobs J.P., Quintessenza J.A., Gaynor J.W., Burke R.P., Mavroudis C. Congenital Heart Surgery Nomenclature and Database Project: aortopulmonary window. Ann Thorac Surg. 2000 Apr;69(4 Suppl):S44-9. doi: 10.1016/s0003-4975(99)01236-9. 
  19. Collinet P., Chatelet-Cheront C., Houze de l"Aulnoit D., Rey C. Prenatal diagnosis of an aortopulmonary window by fetal echocardiography. Fetal Diagn Ther 2002; 17: 302–307.
  20. Engelfriet P.M., Duffels M.G., Möller T., Boersma E., Tijssen J.G., Thaulow E., Gatzoulis M.A., Mulder B.J. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007 Jun;93(6):682-7. doi: 10.1136/hrt.2006.098848. 
  21. El Dick J., El-Rassi I., Tayeh C., Bitar F., Arabi M. Aortopulmonary window in adults: A rare entity leading to Eisenmenger syndrome. Echocardiography. 2019 Jun;36(6):1173-1178. doi: 10.1111/echo.14368.
  22. Cui M., Xia B., Wang H., Liu H., Yin X. A Rare Case of Adult Aortopulmonary Window Combined with Anomalous Origin of the Right Pulmonary Artery from the Aorta Leading to Eisenmenger Syndrome. J Int Med Res. 2021 Jan;49(1):300060520984656. doi: 10.1177/0300060520984656. 
  23. Базылев В.В., Черногривов А.Е., Черногривов И.Е. Крайне редкие врожденные аномалии отхождения одной из коронарных артерий от системы легочной артерии. Москва, 2016.
  24. Chen J., Guo J., Cao S. Unexplained pulmonary hypertension: an overlooked aortopulmonary window. Eur Heart J. 2020 Mar 14;41(11):1217. doi: 10.1093/eurheartj/ehaa021. 
  25. Franzen O., Le T.P., Cesnjevar R., Begemann P., Baldus S. Successful treatment of an adult patient with an aortopulmonary window and severe unilateral pulmonary hypertension. Congenit Heart Dis. 2009 Nov-Dec;4(6):478-80. doi: 10.1111/j.1747-0803.2009.00284.x.
  26. Kouchoukos N.T., Blackstone E.H., Hanley F.L., Kirklin J.K. Kirklin/Barratt-Boyes cardiac surgery: morphology, diagnostic criteria, natural history, techniques, results, and indications. – 4th ed. Philadelphia: Elsevier; 2013.
  27. Myung K. Park. Miscellaneous Congenital Cardiac Conditions in Pediatric Cardiology for Practitioners (Fifth Edition), 2008
  28. Tkebuchava T., von Segesser L.K., Vogt P.R., Bauersfeld U., Jenni R., Künzli A., Lachat M., Turina M. Congenital aortopulumonary window: diagnosis, surgical technique and long-term results. Eur J Cardiothorac Surg. 1997 Feb;11(2):293-7. doi: 10.1016/s1010-7940(96)01048-2. 
  29. Doty D.B., Richardson J.V., Falkovsky G.E., Gordonova M.I., Burakovsky V.I. Aortopulmonary septal defect: hemodynamics, angiography, and operation. Ann Thorac Surg. 1981 Sep;32(3):244-50. doi: 10.1016/s0003-4975(10)61046-6. 
  30. Jacobs M.L. Congenital Heart Surgery Nomenclature and Database Project: truncus arteriosus. Ann Thorac Surg. 2000 Apr;69(4 Suppl):S50-5. doi: 10.1016/s0003-4975(99)01320-x. 
  31. Mori K., Ando M., Takao A., Ishikawa S., Imai Y. Distal type of aortopulmonary window. Report of 4 cases. Br Heart J. 1978 Jun;40(6):681-9. doi: 10.1136/hrt.40.6.681.
  32. Tiradoa A.M., Santos de Sotoa J., Monteroa J.C., Camachoa I.L.G. et al. Aortopulmonary window: clinical assessment and surgical results. Revista Española de Cardiología. Vol. 55. Issue 3. pages 266-270 (March 2002)
  33. Silversides CK, Marelli A, Beauchesne L, et al. Canadian Cardiovascular Society 2009 consensus conference on the management of adults with congenital heart disease: executive summary. Can J Cardiol. 2010;26: 143–50.
  34. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009. 30:2493-2537.
  35. Galie N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2016. 37:67–119.
  36. Ho S.Y., Gerlis L.M., Anderson C., Devine W.A., Smith A. The morphology of aortopulmonary window with regard to their classification and morphogenesis. Cardiol Young 1994;4: 146–55.
  37. Gabriel H.M., Heger M., Innerhofer P., et al. Long-term outcome of patients with ventricular septal defect considered not to require surgical closure during childhood. J Am Coll Cardiol2002;39:1066–1071.
  38. Backer C.L., Mavroudis C., Surgical management of aortopulmonary window: a 40-year experience, European Journal of Cardio-Thoracic Surgery, Volume 21, Issue 5, May 2002, Pages 773–779, https://doi.org/10.1016/S1010-7940(02)00056-8
  39. Soufflet V., Van de B.A., Troost E., et al. Behavior of unrepaired perimembranous ventricular septal defect in young adults. Am J Cardiol 2010; 105: 404–407.
  40. Joud El Dick, Issam El-Rassi, Christelle Tayeh, Fadi Bitar, Mariam Arabi. Aortopulmonary window in adults: A rare entity leading to Eisenmenger syndrome. doi.org/10.1111/echo.14368
  41. Castaneda AR, Jonas RA, Mayer JE Jr, Hanley FL. Cardiac Surgery of the Neonate and Infant. Philadelphia, PA: W.B. Saunders Company; 1994.
  42. Gowda D, Gajjar T, Rao JN, et al. Surgical management of aortopulmonary window: 24 years of experience and lessons learned. Interact Cardiovasc Thorac Surg. 2017;25(2):302–309.
  43. Клинические рекомендации: Легочная гипертензия. http://cr.rosminzdrav.ru/#!/schema/136 (дата обращения 22.03.2020г.).
  44. Бокерия Л.А., Шаталов К.В. Детская кардиохирургия. Руководство для врачей. Москва. НЦССХ им. А.Н. Бакулева. 2016.
  45. Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал 2020; 1: 78-122.
  46. Perloff J.K. Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism. Cardiol Clin 1993;11:689–699.
  47. Mauritz G.J., Rizopoulos D., Groepenhoff H. et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol. 2011. 108(11):1645-50.
  48. Stout K.K., Daniels C.J., Aboulhosn J.A. et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e637-e697. doi: 10.1161/CIR.0000000000000602.
  49. Горбачевский С.В. Легочная гипертензия при дефекте межжелудочковой перегородки. Кардиология, 1990, 30 (3):116-9.
  50. Inuzuka R., Diller G., Borgia F., et al. Comprehensive Use of Cardiopulmonary Exercise Testing Identifies Adults With Congenital Heart Disease at Increased Mortality Risk in the Medium Term. Circulation. 2012; 25: 250–259.
  51. Broberg C.S., Ujita M., Prasad S., et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007;50: 634–642.
  52. Bonderman D., Wexberg P., Martischnig A.M., Heinzl H., Lang M.B., Sadushi R., Skoro-Sajer N., Lang I.M. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J 2011;37:1096–1103.
  53. Rich J.D., Thenappan T., Freed B., Patel A.R., Thisted R.A., Childers R., Archer S.L. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol 2013;167:669–676.
  54. Sun P.Y., Jiang X., Gomberg-Maitland M., Zhao Q.H., He J., Yuan P., Zhang R., Jing Z.C. Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest 2012;141:374–380.
  55. Blieden L.C., Moller J.H. Aorticopulmonary septal defect. An experience with 17 patients. Br Heart J. 1974;36(7):630-635. doi:10.1136/hrt.36.7.630
  56. McElhinney D.B., Reddy V.M., Tworetzky W., Silverman N.H., Hanley .FL. Early and late results after repair of aortopulmonary septal defect and associated anomalies in infants <6 months of age. Am J Cardiol. 1998 Jan 15;81(2):195-201. doi: 10.1016/s0002-9149(97)00881-3. 
  57. Шиллер Н.Б., Осипов М.А. Клиническая эхокардиография. Медпресс-информ. 2021.
  58. Balaji S., Burch M., Sullivan I.D. Accuracy of cross-sectional echocardiography in diagnosis of aortopulmonary window. Am J Cardiol. 1991 Mar 15;67(7):650-3. doi: 10.1016/0002-9149(91)90910-d.
  59. Chellappan S., Katewa A., Sathe Y.C. Transesophageal Echocardiography in a Distal Aortopulmonary Window. J Cardiovasc Echogr. 2016;26(4):131-134. doi:10.4103/2211-4122.192182
  60. Deepak G., Trushar G., Nageswar R., Praveen C., Aaditya S., Naveen P., Neelam D., Surgical management of aortopulmonary window: 24 years of experience and lessons learned, Interactive CardioVascular and Thoracic Surgery, Volume 25, Issue 2, August 2017, Pages 302–309, https://doi.org/10.1093/icvts/ivx099
  61. Myung K. Park. Pediatric Cardiology for Practitioners. Mosby; 6 edition, 2014.-688 p.
  62. Broberg C.S., Ujita M., Prasad S., et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007;50: 634–642.
  63. Debl K., Djavidani B., Buchner S., et al. Quantification of left-to-right shunting in adult congenital heart disease: phase-contrast cine MRI compared with invasive oximetry. Br J Radiol. 2009; 82(977):386-91.
  64. Saremi F. Cardiac CT and MR for Adult Congenital Heart Disease. Springer. 2014.
  65. Engelfriet P.M., Duffels M.G., Möller T., et al. // Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease.// Heart. 2007; 93 (6): 682-7.
  66. Baumgartner H.,  De Backer J., Babu-Narayan S.V. et al. 2020 ESC Guidelines for themanagement of adult congenital heart disease. The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC)//European Heart Journal (2020) 00, 1-83.
  67. Zabal C., García-Montes J.A., Buendía Hernández A., et al. Percutaneous closure of hypertensive ductus arteriosus. Heart. 2010;96:625–9.
  68. Yan C., Zhao S., Jiang S., et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart. 2007; 93:514–8.
  69. Sitbon O., Humbert M., Jaı¨s X., Ioos V., Hamid A.M., Provencher S., Garcia G., Parent F., Herve P., Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105–3111.
  70. Barst R., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski A., Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(Suppl 1):S40–S47.
  71. Knuuti J., Wijns W., Saraste A., et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2019 Aug 31. pii: ehz425.
  72. Kawata H., Kishimoto H., Ueno T., Nakajima T., Inamura N, Nakada T. Repair of aortopulmonary window in an infant with extremely low birth weight. Ann Thorac Surg. 1996 Dec;62(6):1843-5. doi: 10.1016/s0003-4975(96)00550-4.
  73. Lin M.C., Wang C.C., Fu Y.C. Hybrid therapy for interrupted aortic arch with aortopulmonary window in a low birth weight infant. Catheter Cardiovasc Interv. 2011 Nov 15;78(6):945-7. doi: 10.1002/ccd.23160. 
  74. Saxena A., Relan J., Agarwal R., et al. Working group on Management of Congenital Heart Disease in India. Indian Guidelines for Indications and Timing of Intervention for Common Congenital Heart Diseases: Revised and Updated Consensus Statement of the Working Group on Management of Congenital Heart Diseases. Abridged Secondary Publication. Indian Pediatr. 2020 Feb 15;57(2):143-157. 
  75. Hansmann G. Pulmonary Hypertension in Infants, Children, and Young Adults. J Am Coll Cardiol. 2017 May 23;69(20):2551-2569. doi: 10.1016/j.jacc.2017.03.575.
  76. Kaemmerer H., Apitz C., Brockmeier K., et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018; 272S:79-88.
  77. Dickstein K. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388–2442.
  78. Grünig, E., Benjamin, N., Krüger, U., et al. General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018.
  79. Buchhorn R., Hulpke-Wette M., Hilgers R., Bartmus D., Wessel A., Bürsch J. Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PRO-INFANT Trial. Congestive heart failure in infants treated with propanol. Int J Cardiol. 2001 Jul;79(2-3):167-73. doi: 10.1016/s0167-5273(01)00413-2.
  80. Jentzer, J.C., Mathier, M.A. Pulmonary Hypertension in the Intensive Care Unit. Journal of Intensive Care Medicine. 2015; 31(6): 369–385.
  81. Чазова И.Е., Авдеев С.Н., Царева Н.А., др. Клинические рекомендации по диагностике и лечению легочной гипертензии. Тер.архив 2014; 9: 4–23.
  82. Чазова И.Е., Мартынюк Т.В., др. Диагностика и лечение легочной гипертензии. Российские рекомендации. Кардиоваскулярная терапия и профилактика 2007; 6: Приложение 2.
  83. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003; 2:123-137.
  84. Galie` N, Ghofrani HA, Torbicki A, et al, the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148–2157.
  85. Евтушенко А.В. Оценка фармакологических параметров препарата мацитентан – нового антагониста рецепторов эндотелина для лечения легочной артериальной гипертензии. Кардиология 2015; 3: 81-83.
  86. Gatzoulis M.A., Beghetti M., Galie N., et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. Int J Cardiol 2008; Vol.127 (1): 27-32.
  87. Dimopoulos K., Inuzuka R., Goletto S., et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010;121:20–5.
  88. Baptista R., Castro G., da Silva A.M., et al. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. Rev Port Cardiol. 2013;32:123–9.
  89. Rubin L.J., Badesch D.B., Barst R.J., Galie` N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.
  90. Humbert M., Barst R.J., Robbins I.M., Channick R.N., Galie` N., Boonstra A., Rubin L.J., Horn E.M., Manes A., Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353–359.
  91. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., Badesch D.B., Roux S., Rainisio M., Bodin F., Rubin L.J. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119–1123.
  92. Simonneau G., Torbicki A., Hoeper M.M., Delcroix M., Karlocai K., Galie` N., Degano B., Bonderman D., Kurzyna M., Efficace M., Giorgino R., Lang I.M. Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012;40:874–880.
  93. Chen S.L., Zhang F.F., Xu J., Xie D.J., Zhou L., Nguyen T., Stone G.W. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 2013;62: 1092–1100.
  94. Gatzoulis M.A. Landzberg M., BeghettiM.. et al. Evaluation of Macitentan in Patients with Eisenmenger Syndrome: Results from the Randomized, Controlled MAESTRO Study. Circulation 2019; Vol.139 (1): 51–63.
  95. Singh T.P., Rohit M., Grover A., et al. A randomized, placebocontrolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151: 851.e1–851.e5.
  96. Mukhopadhyay S., Sharma M., Ramakrishnan S., et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006; 114: 1807–1810.
  97. McLaughlin V., Channick R.N., Ghofrani H.A., Lemarie´ J.C., Naeije R., Packer M., Souza R., Tapson V.F., Tolson J., Al Hit Hi, Meyer G., Hoeper M.M. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015;46:405–413.
  98. Dardi F., Manes A., Palazzini M., Bachetti C., Mazzanti G., Rinaldi A., Albini A., Gotti E., Monti E., Bacchi Reggiani M.L., Galie` N. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J 2015;46:414–421.
  99. Galie` N., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010;31: 2080–2086.
  100. Sitbon O., Jaı¨s X., Savale L., Cottin V., Bergot E., Macari E.A., Bouvaist H., Dauphin C., Picard F., Bulifon S., Montani D., Humbert M., Simonneau G. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43:1691–1697.
  101. Galie` N., Barbera J.A., Frost A., Ghofrani A., Hoeper M., Mc Laughlin V.V., Peacock A., Simonneau G., Vachiery J.L., Grunig E., Oudiz R.G., Vonk-Nordegraaf A., White J., Blair C., Gillies H.C., Miller L., Harris J.H.N., Langley J., Rubin L.J. Initial Use of Ambrisentan plus Tadalafi in Pulmonary Arterial Hypertension. New Engl J Med 2015; 379(9):834–844.
  102. Шарыкин А.С. Врожденные пороки сердца. Руководство для педиатров, кардиологов, неонатологов. М.: Теремок; 2005.
  103. Talwar S., Siddharth B., Kumar G., et al, Aortopulmonary window: results of repair beyond infancy, Interactive CardioVascular and Thoracic Surgery, Volume 25, Issue 5, November 2017, Pages 740–744, https://doi.org/10.1093/icvts/ivx158
  104. El Dick J., El-Rassi I., Tayeh C., Bitar F., Arabi M. Aortopulmonary window in adults: A rare entity leading to Eisenmenger syndrome. Echocardiography. 2019 Jun;36(6):1173-1178. doi: 10.1111/echo.14368. 
  105. Cui M., Xia B., Wang H., Liu H., Yin X. A Rare Case of Adult Aortopulmonary Window Combined with Anomalous Origin of the Right Pulmonary Artery from the Aorta Leading to Eisenmenger Syndrome. J Int Med Res. 2021 Jan;49(1):300060520984656. doi: 10.1177/0300060520984656.
  106. Thirunavukkarasu B., Kithan L.S., Kumar N., Jain A., Bal A. Fatal outcome of congenital aortopulmonary window with patent ductus arteriosus complicating pregnancy. Autops Case Rep. 2021 Apr 15;11:e2021265. doi: 10.4322/acr.2021.265. 
  107. Khanna S., Mahajan S., Halder V., Gowda N. Incidental diagnosis of a large aortopulmonary window with reversible pulmonary arterial hypertension in adult age and its surgical management. J Card Surg. 2020 Jun;35(6):1364-1367. doi: 10.1111/jocs.14569. 
  108. Kose M., Ucar S., Emet S., Akpinar T.S., Yalin K. A Case of Aortopulmonary Window: Asymptomatic until the First Pregnancy. Case Rep Cardiol. 2015;2015:935253. doi: 10.1155/2015/935253.
  109. Le Bret E., Lupoglazoff J.M., Bachet J., Carbognani D., Bouabdallah K., Folliguet T., Laborde F. Pulmonary artery dissection and rupture associated with aortopulmonary window. Ann Thorac Surg. 2004 Oct;78(4):e67-8. doi: 10.1016/j.athoracsur.2004.02.041. 
  110. Najm H.K., Jijeh A.M., El Moazamy Y.M., Mufti H.N., Abu-Sulaiman R., Mutairi M.A. Dextrocardia, aortopulmonary window with transposition of the great arteries, case report. J Saudi Heart Assoc. 2010 Apr;22(2):61-4. doi: 10.1016/j.jsha.2010.02.007. 
  111. Weil J. Guidelines for the Management of Congenital Heart Diseases in Childhood and Adolescence. Cardiology in the Young. 2017: 27(Suppl. 3): S1–S105.
  112. Johansson L., Michaelsson M., Westerholm C.J., Aberg T. Aortopulmonary window: a new operative approach. Ann Thorac Surg. 1978 Jun;25(6):564-7. doi: 10.1016/s0003-4975(10)63611-9.
  113. Putnam T.C., Gross R.E. Surgical management of aortopulmonary fenestration. Surgery. 1966 May;59(5):727-35.
  114. Popelová J., Oechslin E., Kaemmerer H., Sutton M. Congenital Heart Disease in Adults 2008 Informa UK Ltd.- 183p. ISBN 13: 978 1 84184 584 5.
  115. Christie J.D., Edwards L.B., Kucheryavaya A.Y. et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult lung and heart-lung transplant report 2012. J. Heart Lung Transplant. 2012; 31:1073–1086.
  116. Fadel E., Mercier O., Mussot S., et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg 2010; 38:277–284.
  117. Feltes T.F., Bacha E., Beekman R.H. 3rd, et al. American Heart Association Congenital Cardiac Defects Committee of the Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Cardiovascular Radiology and Intervention; American Heart Association. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation. 2011 Jun 7;123(22):2607-52. doi: 10.1161/CIR.0b013e31821b1f10.
  118. Krichenko A., Benson L.N., Burrows P., Mo¨es C.A., McLaughlin P., Freedom R.M. Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion. Am J Cardiol. 1989;63:877– 880.
  119. Alsoufi B., Schlosser B., McCracken C., Kogon B., Kanter K., Border W., Sachdeva R. Current Outcomes of Surgical Management of Aortopulmonary Window and Associated Cardiac Lesions. Ann Thorac Surg. 2016 Aug;102(2):608-14. doi: 10.1016/j.athoracsur.2016.02.035.
  120. Yıldırım A., Erdem A., Türkmen Karaağaç A. Transcatheter closure of the aortopulmonary window in a three-month-old infant with a symmetric membranous ventricular septal defect occluder device. Turk Gogus Kalp Damar Cerrahisi Derg. 2021 Jan 13;29(1):101-104. doi: 10.5606/tgkdc.dergisi.2021.20988.
  121. Stamato T., Benson L.N., Smallhorn J.F., Freedom R.M. Transcatheter closure of an aortopulmonary window with a modified double umbrella occluder system. Cathet Cardiovasc Diagn. 1995;35:165–167.
  122. Campos-Quintero A., García-Montes J.A., Zabal-Cerdeira C., Cervantes-Salazar J.L., Calderón-Colmenero J., Sandoval J.P. Transcatheter device closure of aortopulmonary window. Is there a need for an alternative strategy to surgery. Rev Esp Cardiol (Engl Ed) 2019;72:349–351. [PubMed] [Google Scholar]
  123. Trehan V., Nigam A., Tyagi S. Percutaneous closure of nonrestrictive aortopulmonary window in three infants. Catheter Cardiovasc Interv. 2008;71:405–411.
  124. Kosmač B., Eicken A., Kühn A., Heinrich M., Ewert P. Percutaneous device closure of an aortopulmonary window in a small infant. e102-3Int J Cardiol. 2013;168 
  125. Nayak H.K., Islam N., Bansal B.K. Transcatheter closure of aortopulmonary window with Amplatzer duct occluder II. Ann Pediatr Card 2017;10:93-4
  126. Giordano M., Butera G. Percutaneous closure of an aortopulmonary window in a young adult patient: a case report of transcatheter closure with an occluder device, European Heart Journal - Case Reports, Volume 4, Issue 3, June 2020, Pages 1–4, https://doi.org/10.1093/ehjcr/ytaa059
  127. Atiq M., Rashid N., Kazmi K.A., Qureshi S.A. Closure of aortopulmonary window with Amplatzer Duct Occluder device. Pediatr Cardiol 2003;24:298–299. [PubMed] [Google Scholar]
  128. 128. Tulloh R.M., Rigby M.L. Transcatheter umbrella closure of aorto-pulmonary window. Heart 1997;77:479–480.
  129. Timothy F. Feltes, Emile Bacha, Robert H. Beekman, John P. Cheatham, Jeffrey A. Feinstein, Antoinette S. Gomes, Ziyad M. Hijazi et al. Indications for Cardiac Catheterization and Intervention in Pediatric Cardiac disease: a scientific statement from the American Heart Association. // Circulation 2011; 123 (22):2607-52.
  130. Рыбка М.М., Хинчагов Д.Я., Мумладзе К.В., др. Под ред. Л.А.Бокерия. Протоколы анестезиологического обеспечения кардиохирургических операций, выполняемых у новорожденных и детей. Методические рекомендации. М.: НЦССХ им.А.Н. Бакулева РАМН; 2014.
  131. Рыбка М.М., Хинчагов Д.Я. Под ред. Л.А.Бокерия. Протоколы анестезиологического обеспечения кардиохирургических операций, выполняемых при ишемической болезни сердца, патологии клапанного аппарата, нарушениях ритма, гипертрофической кардиомиопатии, аневризмах восходящего отдела аорты у пациентов различных возрастных групп. Методические рекомендации. М.: НЦССХ им.А.Н. Бакулева РАМН; 2015
  132. Hew C.C., Bacha E.A., Zurakowski D., del Nido PJ Jr., Jonas R.A. Optimal surgical approach for repair of aortopulmonary window. Cardiol Young. 2001 Jul;11(4):385-90. doi: 10.1017/s104795110100049x. 
  133. Shyu K. G. et al. Diagnostic accuracy of transesophageal echocardiography for detecting patent ductus arteriosus in adolescents and adults //Chest. – 1995. – Т. 108. – №. 5. – С. 1201-1205.
  134. Aggarwal S. K. et al. Aortopulmonary window in adults: diagnosis and treatment of late‐presenting patients //Congenital heart disease. – 2008. – Т. 3. – №. 5. – С. 341-346.
  135. El Dick J. et al. Aortopulmonary window in adults: a rare entity leading to Eisenmenger syndrome //Echocardiography. – 2019. – Т. 36. – №. 6. – С. 1173-1178.
  136. Kervancioglu S. et al. Aortopulmonary window: a rare adult case demonstration by echocardiography, MRI, CE-MRA and angiography //Cardiovascular and interventional radiology. – 2004. – Т. 27. – №. 2. – С. 175-178.
  137. Doty D. B. et al. Aortopulmonary septal defect: hemodynamics, angiography, and operation //The Annals of thoracic surgery. – 1981. – Т. 32. – №. 3. – С. 244-250.
  138. Kimura-Hayama E. T. et al. Uncommon congenital and acquired aortic diseases: role of multidetector CT angiography //Radiographics. – 2010. – Т. 30. – №. 1. – С. 79-98.
  139. Hovnanian A., Jardim C., Souza R. Aortopulmonary window: a rare cause of pulmonary hypertension //Respiration. – 2008. – Т. 76. – №. 3. – С. 351.
  140. Lowrie L. (2000). Diuretic therapy of heart failure in infants and children. Progress in pediatric cardiology. 12. 45-55. 10.1016/S1058-9813(00)00058-8.
  141. Bhatia S., Mehdi M.Q., Jain S.K. Loop Diuretics in Infants with Heart Failure. Neoreviews. 2021 May;22(5):e309-e319. doi: 10.1542/neo.22-5-e309.
  142. Jothinath K., Balakrishnan S., Raju V., Menon S., Osborn J. Clinical efficacy of levosimendan vs milrinone in preventing low cardiac output syndrome following pediatric cardiac surgery. Ann Card Anaesth. 2021;24(2):217-223. doi:10.4103/aca.ACA_160_19
  143. Barst R., Ivy D., Widlitz A. C. et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension // Clin Pharmacol Ther. 2003, 73: 372–382.
  144. Rosenzweig E. B., Ivy D. D., Widlitz A. et al. Effects of long-term bosentan in children with pulmonary arterial hypertension // J Am Coll Cardiol. 2005, 46: 697–704.
  145. Hislop A., Moledina S., Foster H et al. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J. 2011;38(1):70-77.
  146. Barst R., Ivy D., Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73(4):372-382.
  147. Beghetti M., Haworth S., Bonnet D. et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: The FUTURE-1 study. Br J Clin Pharmacol. 2009;68(6):948-955.
  148. Beghetti M., Hoeper M., Kiely D. et al. Safety experience with bosentan in 146 children 2-11years old with pulmonary arterial hypertension: Results from the european postmarketing surveillance program. Pediatr Res. 2008;64(2):200-204.
  149. Rosenzweig E., Ivy D., Widlitz A. et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(4):697-704.
  150. Ivy D., Rosenzweig E., Lemarie J. et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol. 2010;106(9):1332-1338.
  151. Souza R.o, Pulido T., Channick R.. et al. Long-Term Survival and Safety with Macitentan in Patients with Pulmonary Arterial Hypertension: Results from the SERAPHIN Study and Its Open-Label Extension. Pharmacological treatment of pulmonary hypertension 2017; May 1: A2294-A2294
  152. Moledina S., Hislop A., Foster H. et al. Childhood idiopathic pulmonary arterial hypertension: A national cohort study. Heart 2010;96:1401-6.
  153. Peacock A., Murphy N.., McMurrey,J. et al. An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal 2007;30:104–109.
  154. Souza R.О, Pulido T., Channick R.. et al. Long-Term Survival and Safety with Macitentan in Patients with Pulmonary Arterial Hypertension: Results from the SERAPHIN Study and Its Open-Label Extension. Pharmacological treatment of pulmonary hypertension 2017; May 1: A2294-A2294
  155. Klinger J. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007;28(1):143–167
  156. Shaddy R. (2000). Pulmonary hypertension in pediatric heart transplantation. Progress in pediatric cardiology. 11. 131-136. 10.1016/S1058-9813(00)00040-0.
  157. Borg GAV. Psycho-physical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377 - 381,
  158. Borg, G. Borg"s Perceived Exertion and pain Scales. USA: Human Kinetics, 1998, p. 2.
  159. Grant S, Aitchison T, Henderson E, Christie J, Zare S, McMurray J, Dargie H. A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest. 1999 Nov; 116(5): 1208 – 17
  160. "ATS statement: guidelines for the six-minute walk test." Am J Respir Crit Care Med 166(1): 111 - 117.
  161. Borg GA (1982). "Psychophysical bases of perceived exertion". Med Sci Sports Exerc. 14 (5): 377–81. doi:10.1249/00005768-198205000-00012
  162. Malhotra R, Hess D, Lewis GD, Bloch KD, Waxman AB, Semigran MJ. Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. Pulm Circ. 2011;1(2):250-258. doi:10.4103/2045-8932.83449
  163. Сакалаускене Г., Цивинскене Г., Антушевас А., Цивинскас П. Фармакологические свойства петлевых диуретиков и их клинические эффекты. Кардиология. 2018;58(1):72–83.
  164. Курлыкина Н. В., Середенина Е. М., Орлова Я. А. Современные аспекты применения петлевых диуретиков при сердечной недостаточности. Терапевтический архив. 2017;89(9):115-119. https://doi.org/10.17116/terarkh2017899115-119.
  165. Бизунок, Н. А. Б59 Мочегонные средства : учеб.-метод. пособие / Н. А. Бизунок, А. В. Гайдук. – Минск : БГМУ, 2016. – 36 с. ISBN 978-985-567-557-1.
  166. Andrews LM, Puiman PJ, van der Sijs H, van Beynum IM. Een zuigeling met een digoxine-intoxicatie [A baby with digoxin toxicity]. Ned Tijdschr Geneeskd. 2015;159:A8706. Dutch. PMID: 25944069.
  167.  Poole-Wilson PA, Robinson K. Digoxin--a redundant drug in congestive cardiac failure. Cardiovasc Drugs Ther. 1989 Jan;2(6):733-41. doi: 10.1007/BF00133201.
  168. Jain S., Vaidyanathan B. Digoxin in management of heart failure in children: Should it be continued or relegated to the history books?. Ann Pediatr Cardiol. 2009;2(2):149-152. doi:10.4103/0974-2069.58317
  169. Moreno-Galdó A, Torrent-Vernetta A, de Mir Messa I, Rovira Amigo S, Gran Piña F, Gartner S, Albert Brotons D. Use of inhaled iloprost in children with pulmonary hypertension. Pediatr Pulmonol. 2015 Apr;50(4):370-9. doi: 10.1002/ppul.23044.
  170. Alehan D, Yıldırım I, Sahin M, Ozkutlu S, Ozer S, Karagöz T. Long-term inhaled iloprost use in children with pulmonary arterial hypertension. Cardiol Young. 2012 Aug;22(4):396-403. doi: 10.1017/S1047951111001843. 
  171. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, Ivy DD, Jais X, Schulze-Neick I, Galiè N, Morganti A, Dingemanse J, Kusic-Pajic A, Berger RM. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol. 2009 Dec;68(6):948-55. doi: 10.1111/j.1365-2125.2009.03532.x.
  172. Keating GM. Macitentan: A Review in Pulmonary Arterial Hypertension. Am J Cardiovasc Drugs. 2016 Dec;16(6):453-460. doi: 10.1007/s40256-016-0188-x. 
  173. Belge C, Delcroix M. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466618823440. doi: 10.1177/1753466618823440.
  174. Albinni S, Pavo I, Kitzmueller E, Michel-Behnke I. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience. Pulm Circ. 2021;11(1):2045894020979503. Published 2021 Jan 20. doi:10.1177/2045894020979503
  175. Durongpisitkul K., Chungsomprasong P., Vijarnsorn Ch. et al. Improved low-risk criteria scores for combination therapy of sildenafil and generic bosentan in patients with congenital heart disease with sever pulmonary hypertension: A prospective open label study. JRSM Cardiovascular Disease. 2021 Jan 21; 10:2048004020982213. https://doi.org/10.1177/2048004020982213 
  176. Vachiery JL., Galie N., Barbera JA., et al. Ambition study group. Initial combination therapy with ambrisentan+tadalafil on pulmonary arterial hypertension – related hospitalization in the AMBITION trial. J Heart Lung Transplant. 2019. Feb; 38 (2): 194-202. Doi: 10.1016/j.healun.2018.11.006.
  177. Dajani A.S., Taubert K.A., Wilson W. et al: Prevention of bacterial endocarditis: Recommendations by the American Heart Association. JAMA, 1997; 277: 1794-1801.
  178. Das B.B., Moskowitz W.B. Butler J. Current and Future Drug and Device therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. Children. 2021, 8, 322. Htpps: //doi.org/10.3390/children8050322
  179. Albinni S, Pavo I, Kitzmueller E, Michel-Behnke I. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience. Pulm Circ. 2021;11(1):2045894020979503. Published 2021 Jan 20. doi:10.1177/2045894020979503
  180. Hansmann G, Meinel K, Bukova M, Chouvarine P, Wåhlander H, Koestenberger M; European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy. J Heart Lung Transplant. 2020 Jul;39(7):695-706. doi: 10.1016/j.healun.2020.03.029. 
  181. Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. J Heart Lung Transplant. 2019 Jan;38(1):43-50. doi: 10.1016/j.healun.2018.09.003.
  182. Simonca L, Tulloh R. Sildenafil in Infants and Children. Children (Basel). 2017;4(7):60. Published 2017 Jul 24. doi:10.3390/children4070060
  183. Dhariwal AK, Bavdekar SB. Sildenafil in pediatric pulmonary arterial hypertension. J Postgrad Med. 2015;61(3):181-192. doi:10.4103/0022-3859.159421
  184. https://clinicaltrials.gov/ct2/show/NCT02562235#moreinfo. Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (PATENT-CHILD)
  185. Spreemann T, Bertram H, Happel CM, Kozlik-Feldmann R, Hansmann G. First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension. Pulm Circ. 2018;8(1):2045893217743123. doi:10.1177/2045893217743123
  186. Rosenzweig E, Ivy D, Doran A, et al., Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, Volume 46, Issue 4, 2005, Pages 697-704, doi.org/10.1016/j.jacc.2005.01.066.
  187. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации. 2020. Министерство Здравоохранения Российской Федерации. https://cr.minzdrav.gov.ru/recomend/159_1

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*